Ten‐year recurrence rates for breast cancer subtypes in the Netherlands: A large population‐based study

Abstract

Here we report for the first time the relation between breast cancer subtypes and 10‐year recurrence rates and mortality in the Netherlands. All operated women diagnosed with invasive non‐metastatic breast cancer in 2005 in the Netherlands were included. Patients were classified into breast cancer subtypes according to ER, PR, HER2 status and grade: luminal A, luminal B, HER2 positive and triple negative. Percentages and hazards of recurrence were compared among subtypes. Adjusted 10‐year overall (OS) and recurrence‐free survival (RFS) were calculated using multivariable Cox regression. Of 8,062 patients, 4,482 (56%) were luminal A, 2,090 (26%) luminal B, 504 (6%) HER2 positive and 986 (12%) triple negative. Local recurrences (7.5%) and distant metastases (25.6%) occurred most often in HER2 positive disease and the least often in luminal A (3.7% and 9.5%, respectively). Regional recurrences were most often diagnosed in triple negative disease (5.2%), and the least often in luminal A (1.7%). HER2 positive and triple negative subtypes had the highest recurrence rates in the second year, while luminal A and B showed a more continuous pattern over time, with lobular tumours recurring more often. After adjustment for differences in baseline characteristics, triple negative disease showed worse 10‐year OS and triple negative and HER2 positive disease had the lowest 10‐year RFS. In the Netherlands, breast cancer subtypes are important predictors for 10‐year recurrence rates. Knowledge on recurrence and survival rates according to these different subtypes, in combination with other prognostic factors, can support patient‐tailored treatment and individualised follow‐up.

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

“…[7][8][9] Other studies have reported worse outcomes for patients with lobular BC after ≥6 years of follow-up. 10,11 Pleomorphic lobular BC is a rare, more aggressive variant of lobular BC and appears to have a dismal prognosis. 12,13 Cancer November 15, 2020…”

Radio‐guided vs clip‐guided localization of nonpalpable mass‐like lesions of the breast from a screened population: A propensity score‐matched study

“…Anyway, these findings should be cautiously taken into account because follow‐up was quite short, being no more than 24 months. HER2‐positive and triple‐negative breast cancers are associated with early events, but luminal cancers (the majority of cases in this series) are more frequently late‐recurring, thus possible recurrences may be missed in the present study …”

“…HER2-positive and triple-negative breast cancers are associated with early events, but luminal cancers (the majority of cases in this series) are more frequently late-recurring, thus possible recurrences may be missed in the present study. 26 No differences were observed in surgery time between ROLL and TCC (respectively, 65 vs 62.9 minutes) despite operative time 34,35 Most of the previous studies were designed before the recent definition of adequate margins for invasive cancer and DCIS, and frequently patients with benign or uncertain lesions were included, conversely to the present study. 8,[27][28][29][30][31][32][33] Furthermore, adequacy of resection has been often evaluated on specimen volumes or weight, kind of studies since adequacy of resection is the main end-point for breast-conserving surgery of nonpalpable cancers, and current imprecisions and heterogeneity in volumes measurement have led to inconsistent or controversial results.…”

Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine

“…The risk of developing brain metastases for the basal-like and HER2-positive subtypes is four times greater than for the luminal A/B subtypes [17]. Moreover, basal-like and HER-2-positive tumors are associated with early relapse [18,19].…”